Loading...
•
Sep 30
TG Therapeutics Q3 2025 Earnings Report
TG Therapeutics reported strong Q3 results driven by surging BRIUMVI sales and a significant tax benefit.
Key Takeaways
TG Therapeutics posted a sharp increase in revenue and net income in Q3 2025, driven by strong sales of BRIUMVI and a one-time tax benefit. Operating income more than doubled year-over-year as revenue expanded and costs rose at a slower pace.
BRIUMVI U.S. net sales reached $152.9M in Q3 2025
EPS surged to $2.43 driven by a one-time $365M tax benefit
Operating income more than doubled YoY to $29.4M
Full-year revenue and BRIUMVI sales guidance were both raised
TG Therapeutics
TG Therapeutics
TG Therapeutics Revenue by Segment
TG Therapeutics Revenue by Geographic Location
Revenue by Segment
BRIUMVI Revenue
CapyFin.comLicensing & Other Rev Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.com Forward Guidance
TG Therapeutics raised its full-year revenue and BRIUMVI sales targets based on strong Q3 momentum.
Positive Outlook
- Raised full-year BRIUMVI U.S. net revenue guidance to ~$585M
- Raised global full-year revenue guidance to ~$600M
- BRIUMVI now approved in multiple international markets
- Ongoing Phase 3 trials for subcutaneous and simplified dosing regimens
- Completed $100M share repurchase and authorized an additional $100M
Challenges Ahead
- R&D expenses increased due to trial expansion
- SG&A costs rose with commercial scale-up
- Product revenue remains heavily reliant on BRIUMVI
- No update on GAAP vs non-GAAP EPS provided
- Income boosted by one-time $365M tax benefit, not recurring